Eliza began reporting on health and medical science in 2018 while completing her Master’s degree in Journalism at City, University of London. During her degree program she interned at C+D and on the London Evening Standard’s health desk. In the years since, Eliza has written about everything from mid-stage drug development to market access for medicines and devices in the EU and beyond. Her work explores the trials and tribulations of securing reimbursement for medical products in Europe, and Eliza is particularly interested in the challenges of funding innovation in health care. Eliza has lived in London since 2017 and is originally from Cheshire, in the north west of England. She has a BA in English Literature from the University of Manchester and is in the process of completing a second undergraduate degree in Biomedicine from Birkbeck College, an evening university that is part of the University of London.
Latest from Eliza Slawther
The European Medicines Agency says that a regulatory reliance pilot that it is supporting to speed up assessments of post-approval changes appears to be accelerating evaluation timelines in non-EU countries.
Sponsors can expect faster evaluation processes for key medicines and greater support in mitigating medicines supply shortages this year as part of the European Medicines Agency’s digital transformation overhaul.
The European Medicines Agency’s chief medical officer Steffen Thistrup argued that patients are able to understand the “complex regulatory and scientific issues” that the EMA committees discuss when they assess drugs.
In light of the UK’s MHRA announcing a major overhaul of its clinical trial legislation, the agency’s deputy director for clinical investigations and trials Andrea Manfrin tells the Pink Sheet what sponsors can expect from the new regulation.
Companies that use the European Medicines Agency as a reference regulator for the UK’s International Recognition Procedure can expect a faster approval than those that use other national regulators, such as those in the US and Canada, an MHRA spokesperson has said.
The Council of the EU wants to adopt its negotiating position on the reform of the general pharmaceutical legislation “sooner, rather than later,” but divergence between member states could push negotiations back another year, a European Commission policy officer said today.